Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals

Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers

(2011) Lingzhi Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long-Term Safety from the Raltegravir Clinical Development Program

(2011) Hedy Teppler et al.   CURRENT HIV RESEARCH

Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

(2011) J. Ashby et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration

(2011) A. Fayet Mello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

(2011) D. Cattaneo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor

(2011) Diana M. Brainard et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration

(2010) Silvia Baroncelli et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers

(2010) M. Neely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

(2010) José Moltó et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

(2010) Li Zhu et al.   ANTIVIRAL THERAPY

Raltegravir

(2010) Jamie D. Croxtall et al.   DRUGS

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies

(2010) David M Burger   Expert Opinion on Drug Metabolism & Toxicology

Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures

(2010) Alexandra U Scherrer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

(2010) D. da Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Integrase inhibitors in the treatment of HIV-1 infection

(2010) W. G. Powderly   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics

(2010) Diana M. Brainard et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients

(2010) Dario Cattaneo et al.   THERAPEUTIC DRUG MONITORING

Effects of Omeprazole on Plasma Levels of Raltegravir

(2009) Marian Iwamoto et al.   CLINICAL INFECTIOUS DISEASES

Sex Differences in Pharmacokinetics and Pharmacodynamics

(2009) Offie P. Soldin et al.   CLINICAL PHARMACOKINETICS

Drug Interactions with New and Investigational Antiretrovirals

(2009) Kevin C. Brown et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

(2009) LA Wenning et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification and Profiling of Circulating Metabolites of Atazanavir, a HIV Protease Inhibitor

(2009) R. t. Heine et al.   DRUG METABOLISM AND DISPOSITION

Gender and interindividual variability in pharmacokinetics

(2009) Jean-Marie Nicolas et al.   DRUG METABOLISM REVIEWS

Analysis of inherited genetic variations at theUGT1locus in the French-Canadian population

(2009) Vincent Ménard et al.   HUMAN MUTATION

A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine

(2009) A. Fayet et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

(2008) M. S. Anderson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

(2008) M. Iwamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

(2008) L. A. Wenning et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

(2008) Marian Iwamoto et al.   CLINICAL INFECTIOUS DISEASES